A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)
Pembrolizumab (also known by the brand name Keytruda) is an immunotherapy medicine used to treat several types of cancer, including skin, kidney, and lung cancer. It is normally given through a drip into a vein (intravenously), which can take time and requires inserting a needle into a vein at every visit. In this Phase 2 study, researchers are testing a newer version of pembrolizumab that is given as an injection just under the skin (subcutaneously). This type of injection takes only a few minutes to give. The main goal of the study is to see which method patients prefer and why. Participants will share their views using simple questionnaires. The study also checks the safety of the new injection to ensure it is well tolerated.
Auf einen Blick
Worum geht es in dieser Studie?
Pembrolizumab is a widely used immunotherapy drug that helps your body's immune system fight cancer cells. Currently, people having this treatment usually receive it through a drip into a vein. While this works well, having a drip can mean spending several hours at the hospital, and some people find having a needle put into their vein uncomfortable or difficult.
Scientists have developed a new version of the medicine that can be given as a simple injection under the skin, similar to how some diabetes treatments are given. It contains an added ingredient that helps the medicine absorb smoothly into the body. This new method could cut the treatment time down to just a few minutes, potentially saving patients time and making hospital visits less stressful.
This clinical trial is designed to find out directly from patients how the two methods compare. Participants will try the treatments and answer questions about their comfort, convenience, and overall satisfaction. Understanding patient preferences helps doctors choose the best, most comfortable ways to deliver cancer care in the future.
Wichtige Erkenntnisse
- Tests a new under-the-skin injection of pembrolizumab against the standard drip into a vein.
- Open to adults with melanoma, kidney cancer, or non-small cell lung cancer.
- Designed to see which method patients find easier, quicker, and more comfortable.
- Patients fill out simple surveys to share their personal preferences and reasons.
- Taking part is voluntary, and you can withdraw at any point without losing standard care.
Wer könnte berechtigt sein?
This trial is for adults aged 18 and over who have been diagnosed with advanced melanoma (a type of skin cancer), non-small cell lung cancer, or renal cell carcinoma (a type of kidney cancer).
To take part, you must be in a position where treatment with pembrolizumab is recommended for your specific condition. You should also be generally well enough to attend regular hospital appointments and complete questionnaires about your care.
People who have certain other serious medical conditions, active autoimmune diseases, or who are unable to receive immunotherapy medicines may not be able to join. Your cancer doctor will check your full medical history to see if the study is suitable for you.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- I am aged 18 or older.
- I have been diagnosed with melanoma, kidney cancer, or non-small cell lung cancer.
- My cancer specialist has discussed pembrolizumab (Keytruda) as an appropriate treatment for me.
- I am able to attend regular clinic visits for treatment and monitoring.
- I am willing to complete brief questionnaires about my treatment experience.
Was beinhaltet die Teilnahme?
If you decide to join this study, you will attend hospital visits where you will receive your cancer medicine. Over the course of the study, you will experience the treatment given both as a standard drip into a vein and as a quick injection under the skin.
After trying both methods, you will be asked to fill in straightforward questionnaires about which method you preferred and why. If you continue on the trial, you may be able to choose which method you use for the rest of your treatment. Throughout the study, doctors and nurses will check your health, run routine blood tests, and monitor you closely for any side effects. Your total time in the study will depend on how your cancer responds to the medicine.
Potenzielle Risiken und Vorteile
Standorte (2)
- —UnbestätigtPolen
- —UnbestätigtFrankreich
Häufige Fragen
What is the difference between a drip and an under-the-skin injection?
A drip delivers medicine slowly into a vein in your arm and can take 30 minutes or more. An under-the-skin injection goes just beneath the surface of the skin, usually on your tummy or thigh, and takes only a few minutes.
Is the new injection just as effective at treating cancer?
The medicine itself (pembrolizumab) is the same active treatment. Earlier research has shown that the body absorbs it well when given under the skin, but this study focuses specifically on patient comfort and preference.
Will taking the injection hurt?
You might feel a brief sting or pinch when the needle goes in, and you could notice some mild redness or tenderness around the spot afterwards. This is usually mild and settles quickly.
Can I choose which treatment method I stay on?
Yes, part of this study is designed so that once you have tried both ways, you can choose which method you would prefer to receive for the rest of your treatment time on the trial.
Do I have to pay to take part in this clinical trial?
No, all trial medicines, tests, and study-related visits are provided free of charge, and you will not have to pay for your study care.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.